litlas
ログインアカウント作成

Christopher J. Lord

1997–2025 年に発表

157
論文数
43,526
被引用数
99
h 指数
150
i10 指数

被引用数

Christopher J. Lord の年別被引用数1943 年: 被引用 1 件1982 年: 被引用 1 件1990 年: 被引用 1 件1994 年: 被引用 1 件1996 年: 被引用 3 件1997 年: 被引用 3 件1998 年: 被引用 17 件1999 年: 被引用 8 件2000 年: 被引用 20 件2001 年: 被引用 38 件2002 年: 被引用 14 件2003 年: 被引用 8 件2004 年: 被引用 16 件2005 年: 被引用 38 件2006 年: 被引用 60 件2007 年: 被引用 81 件2008 年: 被引用 151 件2009 年: 被引用 216 件2010 年: 被引用 397 件2011 年: 被引用 362 件2012 年: 被引用 392 件2013 年: 被引用 453 件2014 年: 被引用 492 件2015 年: 被引用 470 件2016 年: 被引用 534 件2017 年: 被引用 640 件2018 年: 被引用 691 件2019 年: 被引用 1,881 件2020 年: 被引用 2,336 件2021 年: 被引用 2,227 件2022 年: 被引用 1,905 件2023 年: 被引用 1,349 件2024 年: 被引用 1,922 件2025 年: 被引用 1,009 件2026 年: 被引用 17 件1944〜1981 年は被引用が無いため表示していません1983〜1989 年は被引用が無いため表示していません1991〜1993 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,120 件、この内訳の 27%中国: 引用元論文 2,062 件、この内訳の 10.8%イギリス: 引用元論文 1,911 件、この内訳の 10.1%イタリア: 引用元論文 923 件、この内訳の 4.9%ドイツ: 引用元論文 913 件、この内訳の 4.8%カナダ: 引用元論文 792 件、この内訳の 4.2%フランス: 引用元論文 715 件、この内訳の 3.8%スペイン: 引用元論文 572 件、この内訳の 3%オーストラリア: 引用元論文 530 件、この内訳の 2.8%オランダ: 引用元論文 523 件、この内訳の 2.7%日本: 引用元論文 462 件、この内訳の 2.4%スイス: 引用元論文 363 件、この内訳の 1.9%
0%27%その他 21.6%

機関

分野

  • Medicine50.6%
  • Biochemistry, Genetics and Molecular Biology43.1%
  • Immunology and Microbiology2.9%
  • Computer Science0.8%
  • Engineering0.7%
  • Chemistry0.4%
  • その他1.5%

トピック

  • PARP inhibition in cancer therapy10.6%
  • DNA Repair Mechanisms8.8%
  • Cancer Genomics and Diagnostics3.6%
  • CRISPR and Genetic Engineering3%
  • Cancer-related Molecular Pathways2.8%
  • BRCA gene mutations in cancer2.6%
  • その他68.6%

共著者

全論文

検索で開く
  1. PARP inhibitors: Synthetic lethality in the clinic

    著者: Christopher J. Lord, Alan Ashworth - Science 2017 被引用: 2,937

  2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    著者: Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M.B. Martin, Stephen P. Jackson, Graeme C.M. Smith, Alan Ashworth - Nature 2005 被引用: 6,735

  3. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

    著者: Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Pérez-López, Daniel Nava Rodrigues, Dan R. Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Núria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed A. Hussain, Robert J. Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T. Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono - New England Journal of Medicine 2015 被引用: 2,187

  4. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

    著者: María Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A. Rivas, Rosalind Cutts, Isaac García-Murillas, Alex Pearson, Marta Guzmán, Olga Rodríguez, Judit Grueso, Meritxell Bellet, Javier Cortés, Richard Elliott, Sunil Pancholi, Christopher J. Lord, José Baselga, Mitch Dowsett, Lesley‐Ann Martin, Nicholas C. Turner, Violeta Serra - Cancer Research 2016 被引用: 779

  5. A decade of clinical development of PARP inhibitors in perspective

    著者: J. Mateo, Christopher J. Lord, Violeta Serra, Andrew Tutt, Judith Balmañà, Marta Castroviejo‐Bermejo, Cristina Cruz, Ana Oaknin, Stan B. Kaye, Johann S. de Bono - Annals of Oncology 2019 被引用: 730

  6. BRCAness revisited

    著者: Christopher J. Lord, Alan Ashworth - Nature reviews. Cancer 2016 被引用: 1,250

  7. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

    著者: Diana Zatreanu, Helen M.R. Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Lerin Geo, Diego Grande, Vera Grinkevich, Robert A. Heald, Sophie Langdon, Jayesh B. Majithiya, Claire McWhirter, Niall M.B. Martin, Shaun Moore, Joana Neves, Eeson Rajendra, Marco Ranzani, Theresia A. Schaedler, Martin L. Stockley, Kimberley A. Wiggins, Rachel Brough, Sandhya Sridhar, Aditi Gulati, Nan Shao, Luned Badder, Daniela Novo, Eleanor Knight, Rebecca Marlow, Syed Haider, Elsa Callén, Graeme Hewitt, Joost Schimmel, Remko Prevo, Christina Alli, Amanda Ferdinand, Cameron Bell, Peter Blencowe, Christopher Bot, Mathew Calder, Mark Charles, Jayne Curry, Tennyson Ekwuru, Katherine Ewings, Wojciech Krajewski, Ellen MacDonald, Hollie McCarron, Leon Pang, Chris Pedder, Laurent Rigoreau, Martin E. Swarbrick, Ed Wheatley, Simon N. Willis, Ai Ching Wong, André Nussenzweig, Marcel Tijsterman, Andrew Tutt, Simon J. Boulton, Geoff S. Higgins, Stephen J. Pettitt, Graeme C.M. Smith, Christopher J. Lord - Nature Communications 2021 被引用: 350

  8. The DNA damage response and cancer therapy

    著者: Christopher J. Lord, Alan Ashworth - Nature 2012 被引用: 1,829

  9. ADP‐ribosyltransferases, an update on function and nomenclature

    著者: Bernhard Lüscher, Ivan Ahel, Matthias Altmeyer, Alan Ashworth, Péter Bai, Paul Chang, Michael S. Cohen, Daniela Corda, Françoise Dantzer, Matthew D. Daugherty, Ted M. Dawson, Valina L. Dawson, Sebastian Deindl, Anthony R. Fehr, Karla L. H. Feijs, Dmitri V. Filippov, Jean‐Philippe Gagné, Giovanna Grimaldi, Sebastian Guettler, Nícolas C. Hoch, Michael O. Hottiger, Patricia Korn, W. Lee Kraus, Andreas G. Ladurner, L. Lehtiö, Anthony K. L. Leung, Christopher J. Lord, Aswin Mangerich, Ivan Matić, Jason Matthews, George‐Lucian Moldovan, Joel Moss, Gioacchino Natoli, Michael L. Nielsen, Mario Niepel, F. Nolte, John M. Pascal, Bryce M. Paschal, Krzysztof Pawłowski, Guy G. Poirier, Susan Smith, Gyula Timinszky, Zhao‐Qi Wang, José Yélamos, Xiaochun Yu, Roko Žaja, Mathias Ziegler - FEBS Journal 2021 被引用: 327

  10. The shieldin complex mediates 53BP1-dependent DNA repair

    著者: Sylvie M. Noordermeer, Salomé Adam, Dheva Setiaputra, Marco Barazas, Stephen J. Pettitt, Alexanda K. Ling, Michele Olivieri, Alejandro Álvarez-Quilón, Nathalie Moatti, Michal Zimmermann, Stefano Annunziato, Dragomir B. Krastev, Feifei Song, Inger Brandsma, Jessica Frankum, Rachel Brough, Alana Sherker, Sébastien Landry, Rachel K. Szilard, Meagan Munro, Andrea McEwan, Théo Goullet de Rugy, Zhen‐Yuan Lin, Traver Hart, Jason Moffat, Anne‐Claude Gingras, Alberto Martín, Haico van Attikum, Jos Jonkers, Christopher J. Lord, Sven Rottenberg, Daniel Durocher - Nature 2018 被引用: 675

  11. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

    著者: Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Radoslav Aleksandrov, Maria I. Harrell, Malini Menon, Rachel Brough, James Campbell, Jessica Frankum, Michael Ranes, Helen N. Pemberton, Rumana Rafiq, Kerry Fenwick, Amanda Swain, Sebastian Guettler, Jung-Min Lee, Elizabeth M. Swisher, Stoyno Stoynov, Kosuke Yusa, Alan Ashworth, Christopher J. Lord - Nature Communications 2018 被引用: 447

  12. Targeting the DNA damage response in immuno-oncology: developments and opportunities

    著者: Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie Postel‐Vinay - Nature reviews. Cancer 2021 被引用: 323

  13. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

    著者: Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates - Annals of Oncology 2020 被引用: 481

  14. Structural basis for allosteric PARP-1 retention on DNA breaks

    著者: Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A. Hancock, Jamin D. Steffen, Ramya Billur, Zain M. Hannan, Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, Christopher J. Lord, Tanaji T. Talele, John M. Pascal, Ben E. Black - Science 2020 被引用: 331

  15. PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

    著者: Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, Julien Adam, Daphné Morel, Marlène Garrido, Andrew Lamb, Clémence Henon, Nicolas Dorvault, Mathieu Rouanne, Rebecca Marlow, Ilirjana Bajrami, Marta Llorca Cardeñosa, Asha Konde, Benjamin Besse, Alan Ashworth, Stephen J. Pettitt, Syed Haider, Aurélien Marabelle, Andrew Tutt, Jean‐Charles Soria, Christopher J. Lord, Sophie Postel‐Vinay - Journal of Clinical Investigation 2018 被引用: 324

  16. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

    著者: Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeffrey C. Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord - Nature Communications 2016 被引用: 387

  17. Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance

    著者: Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord - Cancer Discovery 2020 被引用: 184

  18. Resistance to therapy caused by intragenic deletion in BRCA2

    著者: Stacey L. Edwards, Rachel Brough, Christopher J. Lord, Rachael Natrajan, Radost Vatcheva, Douglas A. Levine, Jeff Boyd, Jorge S. Reis‐Filho, Alan Ashworth - Nature 2008 被引用: 1,012

  19. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

    著者: Timothy A. Yap, Brent O’Carrigan, Marina S. Penney, Joline S.J. Lim, Jessica Brown, Maria J. de Miguel, Nina Tunariu, Raquel Pérez-López, Daniel Nava Rodrigues, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Brian Hare, K. Mcdermott, Saira Khalique, Chris T. Williamson, Rachael Natrajan, Stephen J. Pettitt, Christopher J. Lord, Udai Banerji, John R. Pollard, Juanita Lopez, Johann S. de Bono - Journal of Clinical Oncology 2020 被引用: 248

  20. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

    著者: Alan Ashworth, Christopher J. Lord - Nature Reviews Clinical Oncology 2018 被引用: 421

  21. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

    著者: Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth - Cancer Research 2006 被引用: 1,305

  22. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

    著者: Suzanne Carreira, Núria Porta, Sara Arce‐Gallego, George Seed, Alba Llop‐Guevara, Diletta Bianchini, Pasquale Rescigno, Alec Paschalis, Cláudia Bertan, Chloe Baker, Jane Goodall, Susana Miranda, Ruth Riisnaes, Ines Figueiredo, Ana Ferreira, Rita Pereira, Mateus Crespo, Bora Gürel, Daniel Nava Rodrigues, Stephen J. Pettitt, Wei Yuan, Violeta Serra, Jan Rekowski, Christopher J. Lord, Emma Hall, Joaquı́n Mateo, Johann S. de Bono - Cancer Discovery 2021 被引用: 162

  23. Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD

    著者: Graeme Hewitt, Valérie Borel, Sandra Segura‐Bayona, Tohru Takaki, Phil Ruis, Roberto Bellelli, Laura C. Lehmann, Lucia Sommerová, Aleksandra Vančevska, Antonia Tomás‐Loba, Kang Zhu, C.D.O. Cooper, Kasper Fugger, Harshil Patel, Robert Goldstone, Deborah Schneider-Luftman, Ellie Herbert, Gordon Stamp, Rachel Brough, Stephen J. Pettitt, Christopher J. Lord, Stephen C. West, Ivan Ahel, Dragana Ahel, J. Ross Chapman, Sebastian Deindl, Simon J. Boulton - Molecular Cell 2020 被引用: 164

  24. The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

    著者: Dragomir B. Krastev, Shudong Li, Yilun Sun, Andrew J. Wicks, Gwendoline Hoslett, Daniel Weekes, Luned Badder, Eleanor Knight, Rebecca Marlow, Mercedes Pardo, Lu Yu, Tanaji T. Talele, Jiří Bártek, Jyoti S. Choudhary, Yves Pommier, Stephen J. Pettitt, Andrew Tutt, Kristijan Ramadan, Christopher J. Lord - Nature Cell Biology 2022 被引用: 162